With HLB (028300) having closed its final trading day of October, attention is turning to what kind of stock price movement it will show in the November market.

■ Expanded Volatility in After-Hours Trading... Whether It Carries Into the Regular Session Is a Key Point to Watch

As price volatility expanded after the regular session closed on the 30th, whether the upward trend can continue in future trading has emerged as a major point of interest. However, it is difficult to interpret price movements in after-hours trading as carrying over into a rise on the next trading day. This is because after-market and regular sessions may differ in participants and liquidity. Whether the after-hours gains will be maintained on the next trading day requires separate confirmation.

■ Business Progress and Bio Investment Sentiment Must Be Watched Together

An important aspect when examining HLB's future stock price is the company's business progress. In the November market, it is necessary to watch not only HLB's own business-related announcements but also investment sentiment in the domestic bio sector. Bio stocks can react sensitively to individual companies' clinical and approval schedules, and stock price volatility can also expand depending on changes in the market's overall preference for risk assets.

■ FDA Mentions and U.S. Monetary Policy Are Also External Variables

Some observers see FDA mentions as an issue worth paying attention to. U.S. monetary policy is also an external variable. The Federal Reserve's (Fed) future interest rate decisions, U.S. inflation indicators, and Treasury yield movements can affect investment sentiment in the domestic stock market. However, the impact of these macroeconomic variables on HLB's stock price cannot be definitively predicted in a specific direction.

■ What to Check on the First Trading Day of November

On HLB's first trading day of November, it is necessary to check the regular session's opening price, intraday trading volume, and the closing price level together. Depending on whether the upward trend seen in after-hours trading is maintained in the regular session or the gains narrow, the short-term stock price movement may differ.

Ultimately, judging HLB's future stock price requires an approach that distinguishes between short-term price fluctuations and the company's actual business progress. Whether there is an official FDA-related announcement, the new drug development schedule, and supply and demand flows in the regular session are the key variables to confirm in the November market.

[This article is information for investment reference purposes only and does not recommend the purchase or sale of any specific stock. The final judgment and responsibility for stock investment lies with the investor. FDA-related review schedules and approval outcomes may change depending on official announcements. This article was written with partial assistance from AI.]